Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea. The company also develops Probuphine to treat opioid addiction; NeurAxon family for acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; AzaSite for bacterial conjunctivitis; Iluvien to treat diabetic macular edema; Netildex for ocular inflammation; 60P family to treat tropical diseases; Advaxis family to treat HPV-associated cancers and others; PHOTOFRIN for oesophageal and endobronchial cancer, high-grade dysplasia in Barrett's oesophagus, and papillary bladder cancer; ATryn to prevent thromboembolic events; Ember family to treat osteoarthritis, chronic kidney diseases, alport syndrome, and metabolic diseases; and blood factor products. In addition, it develops FLEXISEQ for pain and joint stiffness associated with osteoarthritis; dermo-cosmetic line of products, such as Crescita family, Laboratoire Dr. Renaud, Premiology, and Pro-Derm; SEQuaderma, an active dermatology solution; HandMD skin care products; and UrgentRx, a fast-acting, portable over-the-counter medication. Further, the company develops TULSA-PRO, a medical device for prostate ablation; and 3D family diagnostic and prognostic products for cancers and neurological disorders. Additionally, it finances other life science companies; and invests in life sciences venture capital funds. The company is headquartered in Montreal, Canada.
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Phone514-484-4483
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$11.16 million
Profitability
Miscellaneous
Employees27
OptionableNot Optionable
Knight Therapeutics (TSE:GUD) Frequently Asked Questions
What is Knight Therapeutics' stock symbol?
Knight Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "GUD."
How were Knight Therapeutics' earnings last quarter?
Knight Therapeutics Inc (TSE:GUD) released its quarterly earnings results on Thursday, November, 8th. The company reported $0.03 earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of $0.03. The company had revenue of $3.22 million for the quarter, compared to analysts' expectations of $2.26 million. View Knight Therapeutics' Earnings History.
When is Knight Therapeutics' next earnings date?
What price target have analysts set for GUD?
5 analysts have issued 12-month price targets for Knight Therapeutics' stock. Their forecasts range from C$9.50 to C$10.50. On average, they anticipate Knight Therapeutics' stock price to reach C$10.06 in the next twelve months. This suggests a possible upside of 23.9% from the stock's current price. View Analyst Price Targets for Knight Therapeutics.
What is the consensus analysts' recommendation for Knight Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Knight Therapeutics.
Has Knight Therapeutics been receiving favorable news coverage?
News headlines about GUD stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Knight Therapeutics earned a news impact score of 0.7 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
Who are some of Knight Therapeutics' key competitors?
Some companies that are related to Knight Therapeutics include Acerus Pharmaceuticals (ASP), Aequus Pharmaceuticals (AQS), Amryt Pharma (AMYT), Aphria (APH), Aurora Cannabis (ACB), Bausch Health Companies (BHC), Benchmark (BMK), Biosyent (RX), Cannabis Science (CBIS), Cannpal Animal Therapeutics (CP1), Canopy Growth (WEED), Charlotte's Web (CWBHF), Choom (CHOOF), Cipher Pharmaceuticals (CPHRF) and Cipher Pharmaceuticals (CPH).
Who are Knight Therapeutics' key executives?
Knight Therapeutics' management team includes the folowing people:
- Mr. Jonathan Ross Goodman BA, LLB, MBA, CEO & Director (Age 50)
- Ms. Samira Sakhia C.A., C.P.A., M.B.A., MBA, BCom, CPA, DPA, CA, Pres, CFO & Director (Age 50)
- Mr. Michel Loustric, Pres of Knight Barbados
- Ms. Amal Khouri, VP of Bus. Devel.
- Ms. Jody Engel, Director of Bus. Devel.
How do I buy shares of Knight Therapeutics?
Shares of GUD and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Knight Therapeutics' stock price today?
One share of GUD stock can currently be purchased for approximately C$8.12.
What is Knight Therapeutics' official website?
How can I contact Knight Therapeutics?
The company can be reached via phone at 514-484-4483.
MarketBeat Community Rating for Knight Therapeutics (TSE GUD)
MarketBeat's community ratings are surveys of what our community members think about Knight Therapeutics and other stocks. Vote "Outperform" if you believe GUD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GUD will underperform the S&P 500 over the long term. You may vote once every thirty days.
